KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.…
KALA BIO Announces Reverse Stock Split
KALA BIO (NASDAQ: KALA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 2.705 USD on 20 November 2026, down 99.7% over 52 weeks. Its 52-week range is 2.650 USD to 2865.00 USD: the price is 99.9% below the high and 2.1% above the low.
Its market capitalisation is 1.74M USD.
KALA BIO reports return on equity of -385.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 7.23M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.